This Article Full Text Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Yokoyama, T. Articles by Harker, L. A. Search for Related Content PubMed PubMed Citation Articles by Yokoyama, T. Articles by Harker, L. A.

(Circulation. 1995;92:485-491.)
© 1995 American Heart Association, Inc.

Articles

Antithrombotic Effects of Orally Active Synthetic Antagonist of Activated Factor X in Nonhuman Primates

Toru Yokoyama, PhD; Andrew B. Kelly, DVM; Ulla M. Marzec, BS; Stephen R. Hanson, PhD; Satoshi Kunitada, PhD; Laurence A. Harker, MD

From the Division of Hematology and Oncology and Yerkes Regional Primate Research Center, Emory University School of Medicine, Atlanta, Ga, and Tokyo Research and Development Center, Daiichi Pharmaceutical Co, Ltd, Tokyo, Japan (S.K.).

Correspondence to Laurence A. Harker, MD, Division of Hematology and Oncology, Emory University School of Medicine, PO Drawer AR, Atlanta, GA 30322.

Background Since activated factor X (FXa) has a central role in hemostasis and thrombosis, it is an attractive target for antithrombotic strategies. Accordingly, we evaluated the relative antihemostatic and antithrombotic effects of an orally active amidinoaryl propanoic acid inhibitor of FXa, APAP, in baboons.

Methods and Results With a two-component thrombogenic device that induced the concurrent formation of both arterial-type platelet-rich and venous-type fibrin-rich thrombus when interposed in chronic exteriorized arteriovenous (AV) femoral shunts flowing at 40 mL/min, thrombus formation was compared for oral versus parenteral APAP by measurement of ¹¹¹In-platelet deposition, ¹²⁵I-fibrin accumulation, thrombotic obstruction of flow, and circulating levels of blood biochemical markers of thrombosis. The direct infusion of APAP (120 µg/min) into AV shunts proximal to thrombogenic devices for 1 hour achieved local drug levels of 4.3±0.4 mg/L and substantially reduced the accumulation of platelets and fibrin in the formation of venous-type fibrin-rich thrombus (P<.01) but not in the formation of platelet-rich arterial-type thrombus (P>.1). APAP was subsequently removed from plasma with plasma clearance rates of T₅₀ of 6.3 minutes and T₅₀ß of 99 minutes. The oral administration of APAP (50 mg/kg) produced peak plasma levels of 3.7±1.4 µg/mL at 30 minutes and gradually declining plasma levels over about 6 to 8 hours, with bioavailability estimated to be approximately 5% to 12%. Oral APAP decreased platelet deposition (P<.01) and fibrin accumulation (P<.05) in venous-type thrombus but failed to decrease platelet or fibrin accumulation in arterial-type thrombus (P>.1 in both cases). Oral and infused APAP prolonged the activated partial thromboplastin time and prevented thrombus-dependent elevations in plasma fibrinopeptide A, thrombin–antithrombin III complex, ß-thromboglobulin, and platelet factor 4 levels. Additionally, APAP produced dose-dependent inhibition of FXa bound to thrombus on segments of vascular graft interposed in exteriorized AV shunts for 15 minutes.

Conclusions An oral synthetic antagonist of FXa, APAP, inhibits the formation of venous-type fibrin-rich thrombus by inactivating bound and soluble FXa without impairing platelet hemostatic function.

Key Words: thrombosis • hemostasis • coagulation • anticoagulants • radioisotopes

This article has been cited by other articles:

				P. P. Dobesh, K. Kim, and Z. Stacy The Future of Anticoagulation Journal of Pharmacy Practice, October 1, 2004; 17(5): 370 - 384. [Abstract] [PDF]

				M. Tobu, O. Iqbal, Q. Ma, C. Schultz, W. Jeske, D. Hoppensteadt, B. Lewis, D. Fareed, and J. Fareed Global Anticoagulant Effects of a Synthetic Anti-Factor Xa Inhibitor (DX-9065a): Implications for Interventional Use Clinical and Applied Thrombosis/Hemostasis, January 1, 2003; 9(1): 1 - 17. [Abstract] [PDF]

				C. K. Dyke, R. C. Becker, N. S. Kleiman, J. S. Hochman, E. G. Bovill, A. M. Lincoff, G. Gerstenblith, V. Dzavik, L. H. Gardner, V. Hasselblad, et al. First Experience With Direct Factor Xa Inhibition in Patients With Stable Coronary Disease: A Pharmacokinetic and Pharmacodynamic Evaluation Circulation, May 21, 2002; 105(20): 2385 - 2391. [Abstract] [Full Text] [PDF]

				U. Rauch, J. I. Osende, V. Fuster, J. J. Badimon, Z. Fayad, and J. H. Chesebro Thrombus Formation on Atherosclerotic Plaques: Pathogenesis and Clinical Consequences Ann Intern Med, February 6, 2001; 134(3): 224 - 238. [Abstract] [Full Text] [PDF]